Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 8
2005 12
2006 6
2007 6
2008 5
2009 3
2010 6
2011 6
2012 8
2013 12
2014 9
2015 25
2016 19
2017 34
2018 36
2019 30
2020 54
2021 41
2022 34
2023 23
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Results by year

Filters applied: . Clear all
Page 1
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. Among authors: barlesi f. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.
Walls GM, Mistry H, Barlesi F, Bezjak A, Pechoux CL, O'Brien M, Van Meerbeeck JP, Blackhall F, Faivre-Finn C. Walls GM, et al. Among authors: barlesi f. Int J Radiat Oncol Biol Phys. 2024 Mar 21:S0360-3016(24)00382-1. doi: 10.1016/j.ijrobp.2024.02.063. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38521132 Free article.
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI, Ott PA, Ferris RL, Cascone T, Schadendorf D, Le DT, Sharma MR, Barlesi F, Sharfman W, Luke JJ, Melero I, Lathers D, Neely J, Suryawanshi S, Sanyal A, Holloway JL, Suryawanshi R, Ely S, Segal NH. Khushalani NI, et al. Among authors: barlesi f. J Immunother Cancer. 2024 Mar 7;12(3):e007364. doi: 10.1136/jitc-2023-007364. J Immunother Cancer. 2024. PMID: 38458639 Free PMC article. Clinical Trial.
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M. Baptiste Oudart J, et al. Among authors: barlesi f. Lung Cancer. 2024 Apr;190:107508. doi: 10.1016/j.lungcan.2024.107508. Epub 2024 Feb 19. Lung Cancer. 2024. PMID: 38428265 Free article. Clinical Trial.
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Danlos FX, et al. Among authors: barlesi f. Cell Death Dis. 2024 Feb 14;15(2):142. doi: 10.1038/s41419-024-06519-7. Cell Death Dis. 2024. PMID: 38355585 Free PMC article. No abstract available.
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A, Belcaid L, Palmieri LJ, Teysonneau D, Cousin S, Spalato-Ceruso M, Aldea M, Vasseur D, Alame M, Blouin L, Soubeyran I, Nicotra C, Ngocamus M, Hollebecque A, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Bayle A, et al. Among authors: barlesi f. Mol Cancer. 2023 Nov 4;22(1):176. doi: 10.1186/s12943-023-01878-9. Mol Cancer. 2023. PMID: 37924050 Free PMC article.
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Vokes EE, et al. Among authors: barlesi f. J Thorac Oncol. 2024 Feb;19(2):285-296. doi: 10.1016/j.jtho.2023.09.1452. Epub 2023 Oct 4. J Thorac Oncol. 2024. PMID: 37797733 Free article. Clinical Trial.
339 results